Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK and Safety of Subcutaneous Pembrolizumab (MK-3475A) vs Intravenous Pembrolizumab in First-line Metastatic NSCLC (PD-L1 TPS ≥50%)
jRCT2031240445Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Cycle 1 AUC0-6wks and Steady-state Cycle 3 Ctrough (model-based). Started Apr 2025; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240445.